Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151304 | 0.88 | PARP1 (0.48) | PARP1RPS6KA3HRH3CYP2D6 | |
| SCHEMBL16151230 | 0.87 | PARP1 (0.47) | PARP1RPS6KA3HRH3CYP2D6 | |
| SCHEMBL15564154 | 0.85 | PARP1 (0.45) | PARP1RPS6KA3HRH3CYP2D6ALDH1A1 | |
| SCHEMBL19187284 | 0.82 | PARP1 (0.58) | PARP1RPS6KA3 | |
| SCHEMBL19187269 | 0.80 | PARP1 (0.41) | PARP1HRH3CYP2D6 | |
| SCHEMBL16150558 | 0.80 | RPS6KA3 (0.47) | PARP1RPS6KA3HRH3 | |
| SCHEMBL16151406 | 0.79 | PARP1 (0.41) | PARP1RPS6KA3HRH3CYP2D6ALDH1A1 | |
| SCHEMBL16151289 | 0.79 | RPS6KA3 (0.46) | PARP1RPS6KA3 | |
| SCHEMBL15563598 | 0.77 | PARP1 (0.62) | PARP1RPS6KA3 | |
| SCHEMBL15563315 | 0.77 | PARP1 (0.62) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981538-B1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | claimed |
| US-9586966-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | claimed |
| EP-2981538-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | F. Hoffmann-La Roche AG (CH) | 2016-02-10 | — | — | EP | claimed |
| US-20160016963-A1 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | claimed |
| WO-2014161801-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-09 | — | — | WO | claimed |
| EP-2981538-B1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9586966-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586966-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586966-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2981538-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | F. Hoffmann-La Roche AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-20160016963-A1 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016963-A1 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016963-A1 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014161801-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016963-A1 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one | DRD3, HTR3C, HTR1D | PARP1 205/4885RPS6KA3 732/4885HRH3 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.